BioCentury This Week

BioCentury 397 - Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.

For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

00:00

Епизоди

14 сеп. 2026

08 сеп. 2026

31 авг. 2026

27 авг. 2026

24 авг. 2026

17 авг. 2026

10 авг. 2026

03 авг. 2026

27 юли 2026

20 юли 2026

15 юли 2026

13 юли 2026

06 юли 2026

29 юни 2026

22 юни 2026

15 юни 2026

10 юни 2026

08 юни 2026

01 юни 2026

26 май 2026

18 май 2026

12 май 2026

11 май 2026

04 май 2026

27 апр. 2026

22 апр. 2026

20 апр. 2026

13 апр. 2026

06 апр. 2026

01 апр. 2026

30 мар. 2026

23 мар. 2026

16 мар. 2026

13 мар. 2026

09 мар. 2026

02 мар. 2026

23 фев. 2026

17 фев. 2026

09 фев. 2026

02 фев. 2026

26 ян. 2026

22 ян. 2026

20 ян. 2026

15 ян. 2026

12 ян. 2026

05 ян. 2026

29 дек. 2025

15 дек. 2025

08 дек. 2025

01 дек. 2025

BioCentury This Week

Епизоди

Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs

Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Ep. 384 - Back to School Special: The global FIH trials race

Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA

Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs

Ep. 380 - AZ-BMS rumors, Replimune, psychedelics

Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data

Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson

Ep. 376 - M&A momentum: 3Q public markets preview

Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

Ep. 374 - Parkinson's deep dive & FDA trial reforms

Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

Ep. 371 - Moving faster at the academia-industry interface

Ep. 370 - Calmer waters for FDA; Servier, Lilly deals

Ep. 369 - ASCO advances, China innovation & U.S. science under threat

Ep. 368 - ASCO Preview, China Policy, ADC Linkers

Ep. 367 - FDA, obesity targets and the rise of DACs

Ep. 366 - Europe's need for speed: Bio€quity takeaways

Ep. 365 - Thin ice for Makary, redosing AAVs

Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies

Ep. 363 - New targets at AACR, biopharma deals, Kurma fund

Ep. 362 - AACR: Data and de-risking

Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers

Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

Ep. 358 - Europe's biotech challenge

Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision

Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN

Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline

Ep. 354 - East-West Summit Takeaways

Ep. 353 - Prasad Departure and Future of Fibrosis Therapies

Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight

Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint

Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA

Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch

Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos

Ep. 346 - 2026 Public Markets Preview

Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN

Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation

Ep. 343 - JPM Deals, Policy Outlook, Approval Trends

Ep. 342 - 2026 Biotech Kickoff

Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI

Ep. 340 - Obesity Data, Kymera & FDA Survey Results

Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult

Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, Cell, Gene Therapy Funding